Chongqing Genrix Biopharmaceutical (SH:688443) Ge Long Hui A P P·2025-09-22 11:56Group 1 - The core point of the article is that Zhixiang Jintai (688443.SH) has signed exclusive cooperation agreements with subsidiaries of Kangzhe Pharmaceutical for two monoclonal antibody injections, which will enhance the company's performance and long-term development [1] Group 2 - Zhixiang Jintai will receive an upfront payment and milestone payments totaling approximately 510 million RMB for the collaboration [1] - The exclusive commercialization rights for the products in mainland China will be granted to Tibet Kangzhe, while RXILIENT will obtain exclusive licensing rights for the Asia-Pacific region, the Middle East, and North Africa [1] - There are uncertainties regarding the drug registration process and commercialization risks associated with the collaboration [1]